Iberdomide Produces a Strong MRD-Negative Myeloma Signal

Phase 3 reporting indicates that iberdomide combined with daratumumab and dexamethasone approximately doubled MRD-negative complete-response rates versus standard therapy. The result is clinically important but provisional because available coverage lacks PFS, OS, mature follow-up, toxicity, and full comparator details; anito-cel adds a promising but early CAR-T safety and response signal in heavily pretreated myeloma.